PlainPharmaWatch

CMS Open Payments · Program Year 2024

Dompe Farmaceutici S.p.A.

Dompe Farmaceutici S.p.A. reported $6,935,889.54 across General Payments, Research, and Ownership to 7 physicians and teaching hospitals across 2,668 transactions.

See the rankings → How this is sourced
$6.9M
All-tracks total
2,668
Transactions
7
Recipients
#222
of 1,925 companies

Dompe Farmaceutici S.p.A. reported $6,935,889.54 across all CMS Open Payments tracks (General + Research + Ownership) to 7 physicians and teaching hospitals in Program Year 2024 - ranking #222 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $11,837.50, averaging $990.8K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer dompe-farmaceutici-s-p-a Dompe Farmaceutici S.p.A.

$6.9M · #222/1,925 · 0.0% industry · PY2024

  • TOT $6.9M
  • RANK #222
  • SHARE 0.0%
  • TXN 2,668
  • RCP 7
  • CAT 1
  • GEN $11.8K
  • TOP1 20.3%
  • PY 2024

Volume peers

Nearest volume peer: Astellas Pharma Inc ($6.9M)

Neurology Practice Consortiu…$7.0MWoven Orthopedic Technologie…$7.0MDompe Farmaceutici S.p.A. (t…$6.9MAstellas Pharma Inc$6.9MAstellas US Technologies$6.9M
All-tracks payment totals near Dompe Farmaceutici S.p.A. (CMS Open Payments PY2024)

Dompe Farmaceutici S.p.A. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Dompe Farmaceutici S.p.A.

$6,935,889.54: that is what Dompe Farmaceutici S.p.A. reported in payments to 7 physicians and teaching hospitals during Program Year 2024, spread across 2,668 transactions ($2.6K per transaction, $990.8K per recipient). The company sits at rank #222 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Consulting Fee" leads the 1-category general-payment breakdown below at $11.8K (100.0% of General Payments, 7 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Across 1 types of general payments, Dompe Farmaceutici S.p.A.'s largest category was "Consulting Fee" at $11.8K - 100.0% of General Payments.

How Dompe Farmaceutici S.p.A. divides its payments

How the reported total splits across payment categories

1. Consulting Fee$11.8K
Payment Type Amount Transactions
Consulting Fee $11.8K 7

Recipient Concentration in General Payments

The five largest recipient relationships account for $10,462.50 (88.4%) of $11,837.50 in this company's General Payments records across 7 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Dompe Farmaceutici S.p.A.

The five named recipients with the highest reported General Payments from this company

Alena Reznik$2.4KGeorge a Cioffi$2.3KRoma Patel$2.3KAhmara G Ross$2.3KDavid Hardten$1.3K
  1. 1

    Alena Reznik

    $2,400.00 across 1 reported transactions

  2. 2

    George a Cioffi

    $2,250.00 across 1 reported transactions

  3. 3

    Roma Patel

    $2,250.00 across 1 reported transactions

  4. 4

    Ahmara G Ross

    $2,250.00 across 1 reported transactions

  5. 5

    David Hardten

    $1,312.50 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Dompe Farmaceutici S.p.A.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Dompe Farmaceutici S.p.A..

Amicus Therapeutics, Inc.

HHI 1692

Bolder Surgical, LLC

HHI 1698

Agilent Technologies, Inc.

HHI 1698

Pediatric Alliance LLC

HHI 1687

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Dompe Farmaceutici S.p.A..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Dompe Farmaceutici S.p.A.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.